Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 4/20 | 0.62 |
| ▸ | PLK4 | O00444 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 13/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.43 |
| ▸ | GSK3B | P49841 | 8/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | IGF1R | P08069 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22600946 | 0.85 | PAK4 (0.59) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL219046 | 0.85 | PAK4 (0.59) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL219241 | 0.82 | PLK4 (0.43) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL173559 | 0.81 | PAK4 (0.55) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL220647 | 0.78 | PAK4 (0.57) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL4072828 | 0.77 | PLK4 (0.40) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL4065934 | 0.77 | PLK4 (0.40) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL218203 | 0.77 | PAK4 (0.51) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL218642 | 0.77 | MEN1 (0.62) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL218565 | 0.77 | PAK4 (0.60) | PAK4PLK4MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114989-B2 | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2012-02-14 | — | — | US | disclosed |
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA R&D (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1899323-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006123113-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ABL1, FLT3, ERBB2 | PAK4 142/4885PLK4 292/4885MEN1 2604/4885 |
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ABL1, FLT3, ERBB2 | PAK4 142/4885PLK4 292/4885MEN1 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.